Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria gonorrhoeae strain FA1090 is a well-characterized laboratory strain of the bacterium that causes gonorrhea, used specifically as a bacterial challenge agent in controlled human infection model (CHIM) studies. In trials conducted by the University of North Carolina at Chapel Hill, a suspension of this strain is administered intraurethrally to healthy male volunteers to experimentally induce a localized urethral infection. This model serves as a research tool to evaluate the efficacy of preventative measures, such as the 4C-MenB (Bexsero) vaccine, in providing cross-protection against Neisseria gonorrhoeae. Originally isolated from a cervical sample of a patient with disseminated gonococcal infection, FA1090 is chosen for its established safety profile and predictable clinical course in experimental settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neisseria gonorrhoeae strain FA1090.